http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 15 Oct 2026 06:24:21 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Guggenheim+Reiterates+Buy+Rating+on+Thermo+Fisher+Scientific+%28TMO%29/27189175.html <p>Guggenheim reiterated a Buy rating and $740.00 price target on Thermo Fisher Scientific (NYSE: TMO)</p><p>For an analyst ratings summary and ratings history on Thermo Fisher Scientific <a href="http://www.streetinsider.com/rating_history.php?q=TMO">click here</a>. For more ratings news on Thermo Fisher Scientific <a href="http://www.streetinsider.com/stock_lookup_news.php?q=TMO&amp;type=analyst">click here</a>.</p><p>Shares of Thermo Fisher Scientific closed at $673.20 yesterday.</p> http://www.streetinsider.com/Analyst+Comments/Guggenheim+Reiterates+Buy+Rating+on+Thermo+Fisher+Scientific+%28TMO%29/27189175.html Thu, 15 Oct 2026 06:24:21 -0400 TMO http://www.streetinsider.com/Analyst+PT+Change/Thermo+Fisher+Scientific+%28TMO%29+PT+Raised+to+%24760+at+TD+Cowen/27178869.html TD Cowen analyst Dan Brennan raised the price target on Thermo Fisher Scientific (NYSE: TMO) to $760.00 (from $675.00) while maintaining a rating. http://www.streetinsider.com/Analyst+PT+Change/Thermo+Fisher+Scientific+%28TMO%29+PT+Raised+to+%24760+at+TD+Cowen/27178869.html Tue, 13 Oct 2026 09:31:04 -0400 TMO http://www.streetinsider.com/Analyst+PT+Change/Thermo+Fisher+Scientific+%28TMO%29+PT+Raised+to+%24730+at+Morgan+Stanley/27177753.html Morgan Stanley analyst Kallum Titchmarsh raised the price target on Thermo Fisher Scientific (NYSE: TMO) to $730.00 (from $650.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Thermo+Fisher+Scientific+%28TMO%29+PT+Raised+to+%24730+at+Morgan+Stanley/27177753.html Tue, 13 Oct 2026 08:24:59 -0400 TMO http://www.streetinsider.com/Analyst+PT+Change/Thermo+Fisher+Scientific+%28TMO%29+PT+Raised+to+%24723+at+Baird/27163592.html Baird analyst Catherine Schulte raised the price target on Thermo Fisher Scientific (NYSE: TMO) to $723.00 (from $686.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Thermo+Fisher+Scientific+%28TMO%29+PT+Raised+to+%24723+at+Baird/27163592.html Thu, 08 Oct 2026 07:23:55 -0400 TMO http://www.streetinsider.com/Analyst+PT+Change/Thermo+Fisher+Scientific+%28TMO%29+PT+Raised+to+%24750+at+Barclays/27156982.html Barclays analyst Luke Sergott raised the price target on Thermo Fisher Scientific (NYSE: TMO) to $750.00 (from $650.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Thermo+Fisher+Scientific+%28TMO%29+PT+Raised+to+%24750+at+Barclays/27156982.html Wed, 07 Oct 2026 03:52:27 -0400 TMO http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/General+News/Mizuho+sees+biopharma+funding+rise+56%25+in+September+on+public+deals/27138671.html <p>Investing.com - Biopharma funding totaled $13.0 billion in September 2026, up 42% from $9.1 billion in August and 56% higher than the prior year, according to BioWorld data highlighted by Mizuho. Public-other financing accounted for 64% of September funding, rising 75% month-over-month and 272% year-over-year.</p><p>Year-to-date biopharma funding reached $89.1 billion through September, up 84% from $48.3 billion in the same period of 2025. IPOs saw the largest year-over-year increase at 281%, followed by follow-on offerings at 159% and public-other financing at 53%. Venture funding posted the smallest gain at 25% year-over-year.</p><p>Third-quarter 2026 biopharma funding totaled $29.5 billion, down 15% from http://www.streetinsider.com/General+News/Mizuho+sees+biopharma+funding+rise+56%25+in+September+on+public+deals/27138671.html Fri, 02 Oct 2026 06:31:11 -0400 CRL DHR TECH TMO http://www.streetinsider.com/General+News/Mizuho+sees+biopharma+funding+rise+56%25+in+September+on+public+deals/27138671.html <p>Investing.com - Biopharma funding totaled $13.0 billion in September 2026, up 42% from $9.1 billion in August and 56% higher than the prior year, according to BioWorld data highlighted by Mizuho. Public-other financing accounted for 64% of September funding, rising 75% month-over-month and 272% year-over-year.</p><p>Year-to-date biopharma funding reached $89.1 billion through September, up 84% from $48.3 billion in the same period of 2025. IPOs saw the largest year-over-year increase at 281%, followed by follow-on offerings at 159% and public-other financing at 53%. Venture funding posted the smallest gain at 25% year-over-year.</p><p>Third-quarter 2026 biopharma funding totaled $29.5 billion, down 15% from http://www.streetinsider.com/General+News/Mizuho+sees+biopharma+funding+rise+56%25+in+September+on+public+deals/27138671.html Fri, 02 Oct 2026 06:31:11 -0400 CRL DHR TECH TMO http://www.streetinsider.com/General+News/Mizuho+sees+biopharma+funding+rise+56%25+in+September+on+public+deals/27138671.html <p>Investing.com - Biopharma funding totaled $13.0 billion in September 2026, up 42% from $9.1 billion in August and 56% higher than the prior year, according to BioWorld data highlighted by Mizuho. Public-other financing accounted for 64% of September funding, rising 75% month-over-month and 272% year-over-year.</p><p>Year-to-date biopharma funding reached $89.1 billion through September, up 84% from $48.3 billion in the same period of 2025. IPOs saw the largest year-over-year increase at 281%, followed by follow-on offerings at 159% and public-other financing at 53%. Venture funding posted the smallest gain at 25% year-over-year.</p><p>Third-quarter 2026 biopharma funding totaled $29.5 billion, down 15% from http://www.streetinsider.com/General+News/Mizuho+sees+biopharma+funding+rise+56%25+in+September+on+public+deals/27138671.html Fri, 02 Oct 2026 06:31:11 -0400 CRL DHR TECH TMO http://www.streetinsider.com/General+News/Mizuho+sees+biopharma+funding+rise+56%25+in+September+on+public+deals/27138671.html <p>Investing.com - Biopharma funding totaled $13.0 billion in September 2026, up 42% from $9.1 billion in August and 56% higher than the prior year, according to BioWorld data highlighted by Mizuho. Public-other financing accounted for 64% of September funding, rising 75% month-over-month and 272% year-over-year.</p><p>Year-to-date biopharma funding reached $89.1 billion through September, up 84% from $48.3 billion in the same period of 2025. IPOs saw the largest year-over-year increase at 281%, followed by follow-on offerings at 159% and public-other financing at 53%. Venture funding posted the smallest gain at 25% year-over-year.</p><p>Third-quarter 2026 biopharma funding totaled $29.5 billion, down 15% from http://www.streetinsider.com/General+News/Mizuho+sees+biopharma+funding+rise+56%25+in+September+on+public+deals/27138671.html Fri, 02 Oct 2026 06:31:11 -0400 CRL DHR TECH TMO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++THERMO+FISHER+SCIENTIFIC++For%3A+Sep+26++Filed+by%3A+JOHNSON+JENNIFER+M/27122632.html si-local-file:///var/storage/secattach/20260929/27122632.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++THERMO+FISHER+SCIENTIFIC++For%3A+Sep+26++Filed+by%3A+JOHNSON+JENNIFER+M/27122632.html Tue, 29 Sep 2026 16:14:00 -0400 TMO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++THERMO+FISHER+SCIENTIFIC++For%3A+Sep+26++Filed+by%3A+Keith+R.+Alexandra/27122633.html si-local-file:///var/storage/secattach/20260929/27122633.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++THERMO+FISHER+SCIENTIFIC++For%3A+Sep+26++Filed+by%3A+Keith+R.+Alexandra/27122633.html Tue, 29 Sep 2026 16:14:00 -0400 TMO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++THERMO+FISHER+SCIENTIFIC++For%3A+Sep+26++Filed+by%3A+Lynch+Karen+S/27122636.html si-local-file:///var/storage/secattach/20260929/27122636.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++THERMO+FISHER+SCIENTIFIC++For%3A+Sep+26++Filed+by%3A+Lynch+Karen+S/27122636.html Tue, 29 Sep 2026 16:14:00 -0400 TMO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++THERMO+FISHER+SCIENTIFIC++For%3A+Sep+26++Filed+by%3A+SPERLING+SCOTT+M/27122639.html si-local-file:///var/storage/secattach/20260929/27122639.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++THERMO+FISHER+SCIENTIFIC++For%3A+Sep+26++Filed+by%3A+SPERLING+SCOTT+M/27122639.html Tue, 29 Sep 2026 16:14:00 -0400 TMO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++THERMO+FISHER+SCIENTIFIC++For%3A+Sep+26++Filed+by%3A+WEISLER+DION+J/27122641.html si-local-file:///var/storage/secattach/20260929/27122641.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++THERMO+FISHER+SCIENTIFIC++For%3A+Sep+26++Filed+by%3A+WEISLER+DION+J/27122641.html Tue, 29 Sep 2026 16:14:00 -0400 TMO